Degradable magnesium alloy angiocarpy bracket with medicine and preparation method thereof

A magnesium alloy stent, magnesium alloy technology, applied in stents, medical science, surgery, etc., can solve problems such as fractures, cracks, affecting the mechanical properties and corrosion resistance of stents, and reduce pitting corrosion, smooth surface, and reduce restenosis. the effect of the incidence of

Inactive Publication Date: 2009-07-01
INST OF METAL RESEARCH - CHINESE ACAD OF SCI
View PDF1 Cites 27 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the rare earth conversion film and anodic oxide film used in the surface protective layer are very brittle, and are prone to cracks or even fractures during the expansion and compression of the stent, affecting the mechanical properties and corrosion resistance of the stent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] The Mg-Zn series magnesium alloy (ZAC8502) is engraved into a bracket by laser processing method, and then the bracket is processed by the following process:

[0022] 1. Pretreatment

[0023] Use mechanical polishing and electrolytic polishing to obtain a smooth stent surface, wash with concentrated hydrofluoric acid (40% weight / volume concentration) and phosphoric acid in a volume ratio of 1:1 to remove scale, corrosion products and others For dirt, the treatment temperature is 30°C, the treatment time is 1 minute, and washed with water. Then use a hydrofluoric acid aqueous solution with a concentration of 5% (weight / volume) at 40° C. to remove the extremely thin oxide film on the surface of the stent and pickling dust for 1 minute, wash with water, and dry.

[0024] 2. Preparation of fluorine-containing conversion coating on the surface

[0025] The composition of the conversion solution is: KH 2 PO 4 : 13.5g / l, K 2 HPO 4 : 27g / l, NaHF 2 : 3-5g / l, the balance i...

Embodiment 2

[0030] The Mg-RE magnesium alloy (WE43) was processed into a cardiovascular stent by laser processing, and the same surface pretreatment process as in Example 1 was adopted. The preparation process of the fluorine-containing conversion film on its surface is as follows: the conversion liquid composition is: 20g / l manganese nitrate, 50g / l sodium dihydrogen phosphate, 2g / l potassium fluoride, and the balance is water; the treatment temperature is 60°C, and the time is 60 minutes, pH is 5, washed with water, dried. In this example, the main component of the fluorine-containing conversion coating is MgF 2 , Mg 3 (PO4) 2 , Mg(OH) 2, MgO. Characterized by energy spectrum, its element content weight ratio is Mg:F:P:O=80:3:8:9, and the thickness of the conversion film is 1 μm.

[0031] The preparation process of the drug-loaded layer of the outer layer is: adopt spraying process, will contain 1-5% (weight / volume) chitosan / polyethylene glycol blend (wherein, chitosan accounts for ...

Embodiment 3

[0034] The Mg-Al series magnesium alloy (AZ31) was prepared into a cardiovascular stent by laser processing, and the same surface pretreatment process as in Example 1 was adopted. The preparation process of the fluorine-containing conversion coating on the surface is as follows: soaking the magnesium alloy bracket in 30% (weight / volume) hydrofluoric acid aqueous solution at 20-40 DEG C for 48 hours, washing with water and drying. In this example, the composition of the fluorine-containing conversion coating is MgF 2 , Mg(OH) 2 . Characterized by energy spectrum, the element content weight ratio is Mg:F:O=90:6:4, and the conversion film thickness is 2 μm. Then, prepare the drug-loaded layer on the outer surface, the preparation process is as in Example 2, the difference is that the drug carrier adopts polytrimethylene carbonate copolymer (P(LA-TMC)), and the therapeutic drug adopts tacrolimus (tacrolimus). ).

[0035] The magnesium alloy stent treated by the above process h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention relates to technical field of biological material, and is especially suitable for surface modification field of biological medical material. Particularly the invention provides a medicine-taking degradable magnesium alloy cardiovascular bracket and a preparing method thereof. The aim of the invention is to reduce the initial degrading speed of magnesium alloy in biosome and carry therapeutic medicine on the surface of magnesium bracket thereby guaranteeing the mechanical performance of magnesium alloy bracket in vivo and better restraining the hyperplasia of newborn tunica interna. A fluoro-containing transition film is prepared on the surface of magnesium alloy bracket, and a medicine-carrying layer is prepared on the outer layer of magnesium alloy bracket. A protecting layer is the fluoro-containing transition film. The fluoro-containing transition film has self-concrescence capability in the degradation process of magnesium alloy and can effectively reduce the in-vivo degradation velocity of magnesium alloy bracket. The surface of degradable magnesium alloy cardiovascular bracket is smooth and is not easily generated with surface cracking and breaking-off. The medicine-taking layer is composed of medicine carrier polymer or protein and therapeutic medicine. The medicine-taking layer can release therapeutic medicine, reduce the generation rate of stenosis after the implantation of bracket and has a control function to the degradation velocity of magnesium alloy bracket.

Description

technical field [0001] The invention relates to the technical field of biomaterials, and is particularly suitable for the field of surface modification of biomedical materials; specifically, it relates to a medicine-carrying degradable magnesium alloy cardiovascular stent and a preparation method thereof. Background technique [0002] In the field of cardiovascular treatment, interventional stent therapy has become the most important means. The drug-loaded metal stent significantly reduces the rate of postoperative restenosis compared with non-stent treatment. However, cardiovascular stents are still mainly made of non-degradable metal materials (such as 316L stainless steel, cobalt-chromium alloy, etc.), which are permanently implanted devices. However, it has permanent physical stimulation to the vascular wall, mismatch with the mechanical properties of non-implanted blood vessels, intimal hyperplasia after long-term implantation, inability to guide postoperative vascular...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L31/16A61L2/12A61F2/82
Inventor 谭丽丽颜廷亭杨柯张炳春肖克沈
Owner INST OF METAL RESEARCH - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap